相似文献
1
[Venetoclax combined with rituximab in the treatment of ibrutinib-resistant patient with chronic lymphocytic leukemia: a case report and literature reviews].
Zhonghua Xue Ye Xue Za Zhi. 2019 Aug 14;40(8):700-702. doi: 10.3760/cma.j.issn.0253-2727.2019.08.018.
2
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
Br J Haematol. 2022 Oct;199(2):239-244. doi: 10.1111/bjh.18357. Epub 2022 Jul 16.
3
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
J Clin Oncol. 2019 Oct 20;37(30):2722-2729. doi: 10.1200/JCO.19.00894. Epub 2019 Jul 11.
4
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2024 Jun;25(6):744-759. doi: 10.1016/S1470-2045(24)00196-7.
5
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Clin Adv Hematol Oncol. 2019 Apr;17(4):214-216.
6
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Lancet Oncol. 2022 Jun;23(6):818-828. doi: 10.1016/S1470-2045(22)00220-0.
7
Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
N Engl J Med. 2019 Aug 22;381(8):789. doi: 10.1056/NEJMc1908754.
8
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.
9
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Blood. 2020 Jun 18;135(25):2266-2270. doi: 10.1182/blood.2020004782.
10
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.
本文引用的文献
1
Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia.
Haematologica. 2019 Jan;104(1):e38-e41. doi: 10.3324/haematol.2018.202085. Epub 2018 Sep 27.
2
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Am J Hematol. 2018 Nov;93(11):1402-1410. doi: 10.1002/ajh.25259. Epub 2018 Oct 9.
3
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.
4
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.
Blood Adv. 2017 May 2;1(12):715-727. doi: 10.1182/bloodadvances.2016003632. eCollection 2017 May 9.
5
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Nat Commun. 2017 Dec 19;8(1):2185. doi: 10.1038/s41467-017-02329-y.
6
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.
7
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Nat Commun. 2016 May 20;7:11589. doi: 10.1038/ncomms11589.
8
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Lancet Oncol. 2014 Sep;15(10):1090-9. doi: 10.1016/S1470-2045(14)70335-3. Epub 2014 Aug 20.
9
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19.
Zotero 插件